vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and BingEx Ltd (FLX). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($263.6M vs $143.2M, roughly 1.8× BingEx Ltd). BALCHEM CORP runs the higher net margin — 14.9% vs 2.2%, a 12.6% gap on every dollar of revenue.
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
BCPC vs FLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $143.2M |
| Net Profit | $39.2M | $3.2M |
| Gross Margin | 35.6% | 10.8% |
| Operating Margin | 19.8% | — |
| Net Margin | 14.9% | 2.2% |
| Revenue YoY | 9.8% | — |
| Net Profit YoY | 16.8% | — |
| EPS (diluted) | $1.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $143.2M | ||
| Q4 25 | $263.6M | — | ||
| Q3 25 | $267.6M | $141.2M | ||
| Q2 25 | $255.5M | $143.0M | ||
| Q1 25 | $250.5M | $141.0M | ||
| Q4 24 | $240.0M | — | ||
| Q3 24 | $239.9M | $164.6M | ||
| Q2 24 | $234.1M | — |
| Q1 26 | — | $3.2M | ||
| Q4 25 | $39.2M | — | ||
| Q3 25 | $40.3M | $6.1M | ||
| Q2 25 | $38.3M | $7.5M | ||
| Q1 25 | $37.1M | $27.6M | ||
| Q4 24 | $33.6M | — | ||
| Q3 24 | $33.8M | $3.4M | ||
| Q2 24 | $32.1M | — |
| Q1 26 | — | 10.8% | ||
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | 11.1% | ||
| Q2 25 | 36.4% | 12.0% | ||
| Q1 25 | 35.2% | 10.0% | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | 11.3% | ||
| Q2 24 | 35.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.8% | — | ||
| Q3 25 | 20.4% | 1.4% | ||
| Q2 25 | 20.1% | 1.9% | ||
| Q1 25 | 20.4% | — | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 20.0% | 4.0% | ||
| Q2 24 | 19.6% | — |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 14.9% | — | ||
| Q3 25 | 15.1% | 4.4% | ||
| Q2 25 | 15.0% | 5.2% | ||
| Q1 25 | 14.8% | 19.6% | ||
| Q4 24 | 14.0% | — | ||
| Q3 24 | 14.1% | 2.1% | ||
| Q2 24 | 13.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.21 | — | ||
| Q3 25 | $1.24 | — | ||
| Q2 25 | $1.17 | — | ||
| Q1 25 | $1.13 | — | ||
| Q4 24 | $1.03 | — | ||
| Q3 24 | $1.03 | — | ||
| Q2 24 | $0.98 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $561.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | — |
| Total Assets | $1.7B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $561.1M | ||
| Q4 25 | $74.6M | — | ||
| Q3 25 | $65.1M | $628.6M | ||
| Q2 25 | $65.4M | $499.4M | ||
| Q1 25 | $49.9M | $592.4M | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $73.7M | $517.4M | ||
| Q2 24 | $63.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.1B | — |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.6B | $926.8M | ||
| Q2 24 | $1.6B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $67.3M | — | ||
| Q3 25 | $65.6M | — | ||
| Q2 25 | $47.3M | — | ||
| Q1 25 | $36.5M | — | ||
| Q4 24 | $52.3M | — | ||
| Q3 24 | $51.3M | — | ||
| Q2 24 | $45.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
FLX
Segment breakdown not available.
